Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $152.15 USD
Change Today +0.15 / 0.10%
Volume 1.0M
BDX On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Open
$152.61
Previous Close
$152.00
Day High
$152.88
Day Low
$151.88
52 Week High
07/31/15 - $152.88
52 Week Low
09/22/14 - $112.15
Market Cap
31.9B
Average Volume 10 Days
897.0K
EPS TTM
$6.40
Shares Outstanding
209.4M
EX-Date
09/4/15
P/E TM
23.8x
Dividend
$2.40
Dividend Yield
1.54%
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Life Sciences segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers. This segment’s products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood and tuberculosis culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. It also offers research and clinical tools, such as fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. In addition, the company develops technologies that address biological analysis protocols, including library preparation of next generation sequencing and genotyping applications. Becton, Dickinson and Company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

30,619 Employees
Last Reported Date: 11/26/14
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $985.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $690.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $721.0K
Executive Vice President and President of Glo...
Total Annual Compensation: $605.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $900.8K
Compensation as of Fiscal Year 2014.

becton dickinson and co (BDX) Key Developments

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2015

Becton, Dickinson and Company has declared a quarterly dividend of 60 cents per common share, payable on September 30, 2015 to holders of record on September 9, 2015. The indicated annual dividend rate is $2.40 per share.

Becton, Dickinson and Company Opens Advance Diabetes Care Facility in Andover, Massachusetts

Becton, Dickinson and Company announced that it has opened its Advanced Diabetes Care facility in Andover, Mass., which will house research and development (R&D) and manufacturing of novel solutions for Type 1 and Type 2 diabetes. The Andover facility, which will serve as the new headquarters for BD's Advanced Diabetes Care platform, incorporates a 'Center of Excellence' model, bringing R&D and manufacturing of solutions for Type 1 and Type 2 diabetes patients under one roof. Approximately 100 associates will be located in the 75,000 square foot facility.

Becton Dickinson and Guidepoint Help Startups Connect to Experts

Becton Dickinson and Guidepoint announced that they are partnering to help provide Guidepoint's expert network services to select healthcare startups. Through the arrangement, Guidepoint will arrange consultations between selected healthcare entrepreneurs and experts in their fields.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $152.15 USD +0.15

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,867 JPY +15.00
Avago Technologies Ltd $125.14 USD -2.51
Boston Scientific Corp $17.34 USD +0.09
Mylan NV $55.99 USD -0.36
Stryker Corp $102.27 USD +0.43
View Industry Companies
 

Industry Analysis

BDX

Industry Average

Valuation BDX Industry Range
Price/Earnings 27.9x
Price/Sales 3.5x
Price/Book 4.4x
Price/Cash Flow 29.5x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit www.bd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.